Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study

Journal of Translational Medicine

Salvador Resino¹  Sonia Vazquez-Morón¹  Cristina Diez²  Francisco Tejerina²  Mónica García-Álvarez¹  Ana Carrero²  Pilar García-Broncano¹  Teresa Aldámiz-Echevarria²  Daniel Pineda-Tenor¹  María A Jiménez-Sousa¹  Juan Berenguer²  María Guzmán-Fulgencio¹ 

[1] Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Carretera Majadahonda-Pozuelo, Km 2.2, Majadahonda, Madrid, 28220, Spain;Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain

关键词: SNPs;    IL7R;    Chronic hepatitis C;    Hepatic fibrosis;    HIV/AIDS;   

Others  :  1221482
DOI  :  10.1186/s12967-015-0577-y

 received in 2014-12-20, accepted in 2015-06-19,  发布年份 2015

【 摘 要 】

Background

Interleukin-7 (IL-7) is a critical factor for T cell development and for maintaining and restoring homeostasis of mature T cells. Polymorphisms at α-chain of the IL-7 receptor (IL7R or CD127) gene are related to evolution of HIV-infection, but there are no data concerning the evolution of hepatitis C virus (HCV) infection. The aim of this study was to analyze the association between IL7R polymorphisms and severe liver disease in HCV/HIV coinfected patients.

Methods

We performed a cross-sectional study in 220 naïve patients who underwent a liver biopsy. IL7R polymorphisms (rs6897932, rs987106 and rs3194051) were genotyped using the GoldenGate ^®assay. The outcome variables were: (a) liver biopsy: advanced fibrosis (F ≥ 3), severe activity grade (A3); (b) non-invasive indexes: advanced fibrosis (APRI ≥1.5 and FIB-4 ≥3.25). Logistic regression analysis was used to investigate the association between IL7R polymorphisms and outcome variables. This test gives the differences between groups and the odds ratio (OR) for liver disease.

Results

Patients with rs6897932 CC genotype had higher likelihood of having A3 than patients with rs6897932 CT/TT (adjusted odds ratio (aOR) = 4.16; p = 0.026). Patients with rs987106 TT genotype had higher odds of having F ≥ 3 (aOR = 3.09; p = 0.009) than rs987106 AA/AT carriers. Finally, patients with rs3194051 AA genotype had higher odds of having severe liver fibrosis (F ≥ 3; APRI ≥1.5, and FIB4 ≥3.25) than patients with rs3194051 AG/GG genotype [aOR = 2.73 (p = 0.010); aOR = 2.52 (p = 0.029); and aOR = 4.01 (p = 0.027); respectively]. The CTA haplotype (comprised of rs6897932, rs987106, and rs3194051) carriers had higher odds of having F ≥ 3 (aOR = 1.85; p = 0.012), APRI ≥1.5 (aOR = 1.94; p = 0.023), and FIB4 ≥3.25 (aOR = 2.47; p = 0.024). Conversely, the CAG haplotype carriers had lower odds of having F ≥ 3 (aOR = 0.48; p = 0.011), APRI ≥1.5 (aOR = 0.48; p = 0.029), and FIB4 ≥3.25 (aOR = 0.29; p = 0.010).

Conclusions

The presence of IL7R polymorphisms seems to be related to severe liver disease in HIV/HCV coinfected patients, because patients with unfavorable IL7R genotypes (rs6897932 CC, rs987106 TT, and rs3194051AA) had a worse prognosis of CHC.

【 授权许可】

   
2015 Guzmán-Fulgencio et al.

【 图 表 】

Figure1.

【 参考文献 】

• [1]Pellegrini M, Calzascia T, Toe JG, Preston SP, Lin AE, Elford AR et al.. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell. 2011; 144:601-613.
• [2]Liang B, Hara T, Wagatsuma K, Zhang J, Maki K, Miyachi H et al.. Role of hepatocyte-derived IL-7 in maintenance of intrahepatic NKT cells and T cells and development of B cells in fetal liver. J Immunol. 2012; 189:4444-4450.
• [3]Noguchi M, Nakamura Y, Russell SM, Ziegler SF, Tsang M, Cao X et al.. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science. 1993; 262:1877-1880.
• [4]Capitini CM, Chisti AA, Mackall CL. Modulating T-cell homeostasis with IL-7: preclinical and clinical studies. J Intern Med. 2009; 266:141-153.
• [5]Paiardini M. Editorial: hijacking the IL-7/IL-7R system in HIV infection. J Leukoc Biol. 2011; 89:491-493.
• [6]Hou L, Jie Z, Desai M, Liang Y, Soong L, Wang T et al.. Early IL-17 production by intrahepatic T cells is important for adaptive immune responses in viral hepatitis. J Immunol. 2013; 190:621-629.
• [7]Shin EC, Park SH, Nascimbeni M, Major M, Caggiari L, de Re V et al.. The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection. J Virol. 2013; 87:4772-4777.
• [8]Larrea E, Riezu-Boj JI, Aldabe R, Guembe L, Echeverria I, Balasiddaiah A et al.. Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes. Gut. 2014; 63:665-673.
• [9]Larrubia JR, Lokhande MU, Garcia-Garzon S, Miquel J, Gonzalez-Praetorius A, Parra-Cid T et al.. Persistent hepatitis C virus (HCV) infection impairs HCV-specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation. J Viral Hepat. 2013; 20:85-94.
• [10]Haralambieva IH, Ovsyannikova IG, Kennedy RB, Vierkant RA, Pankratz VS, Jacobson RM et al.. Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. Vaccine. 2011; 29:7883-7895.
• [11]Sudenga SL, Wiener HW, Shendre A, Wilson CM, Tang J, Shrestha S. Variants in interleukin family of cytokines genes influence clearance of high risk HPV in HIV-1 coinfected African-American adolescents. Hum Immunol. 2013; 74:1696-1700.
• [12]Mazzucchelli RI, Riva A, Durum SK. The human IL-7 receptor gene: deletions, polymorphisms and mutations. Semin Immunol. 2012; 24:225-230.
• [13]Limou S, Melica G, Coulonges C, Lelievre JD, Do H, McGinn S et al.. Identification of IL7RA risk alleles for rapid progression during HIV-1 infection: a comprehensive study in the GRIV cohort. Curr HIV Res. 2012; 10:143-150.
• [14]Rajasuriar R, Booth DR, Gouillou M, Spelman T, James I, Solomon A et al.. The role of SNPs in the alpha-chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART. Genes Immun. 2012; 13:83-93.
• [15]Guzman-Fulgencio M, Berenguer J, Pineda-Tenor D, Jimenez-Sousa MA, Garcia-Alvarez M, Aldamiz-Echevarria T et al.. Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients. Eur J Clin Microbiol Infect Dis. 2015; 34:385-393.
• [16]Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d’Arminio Monforte A et al.. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003; 362:22-29.
• [17]Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D et al.. Changes in causes of death among adults infected by HIV between 2000 and 2005: the “Mortalite 2000 and 2005” surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008; 48:590-598.
• [18]Lo Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB et al.. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014; 160:369-379.
• [19]Lin W, Weinberg EM, Chung RT. Pathogenesis of accelerated fibrosis in HIV/HCV co-infection. J Infect Dis. 2013; 207 Suppl 1:S13-S18.
• [20]Lopez-Dieguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, Berenguer J et al.. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS. 2011; 25:899-904.
• [21]Macias J, Berenguer J, Japon MA, Giron JA, Rivero A, Lopez-Cortes LF et al.. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009; 50:1056-1063.
• [22]Lo Re V 3rd, Kostman JR, Amorosa VK (2008) Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis 12:587–609, ix
• [23]Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008; 22:1979-1991.
• [24]Brau N, Salvatore M, Rios-Bedoya CF, Fernandez-Carbia A, Paronetto F, Rodriguez-Orengo JF et al.. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006; 44:47-55.
• [25](2010) Panel de expertos de Gesida Plan Nacional sobre el Sida y Asociación Española para el Estudio del Hígado: [Recommendations of Gesida/PNS/AEEH for the management and treatment of the adult patient co-infected with HIV and hepatitis A, B and C virus]. Enferm Infecc Microbiol Clin 28:31 e31–31
• [26](2009) Panel de expertos de Gesida y Plan Nacional sobre el Sida: [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Enferm Infecc Microbiol Clin 27:222–235
• [27]Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J et al.. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002; 155:645-653.
• [28]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412-419.
• [29]Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS et al.. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38:518-526.
• [30]Sterling RK, Chiu S, Snider K, Nixon D. The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. Dig Dis Sci. 2008; 53:1375-1382.
• [31]Resino S, Sanchez-Conde M, Berenguer J. Coinfection by human immunodeficiency virus and hepatitis C virus: noninvasive assessment and staging of fibrosis. Curr Opin Infect Dis. 2012; 25:564-569.
• [32]Resino S, Seoane JA, Bellon JM, Dorado J, Martin-Sanchez F, Alvarez E et al.. An artificial neural network improves the non-invasive diagnosis of significant fibrosis in HIV/HCV coinfected patients. J Infect. 2011; 62:77-86.
• [33]Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24:289-293.
• [34]Park JH, Gail MH, Weinberg CR, Carroll RJ, Chung CC, Wang Z et al.. Distribution of allele frequencies and effect sizes and their interrelationships for common genetic susceptibility variants. Proc Natl Acad Sci USA. 2011; 108:18026-18031.
• [35]Fan JB, Oliphant A, Shen R, Kermani BG, Garcia F, Gunderson KL et al.. Highly parallel SNP genotyping. Cold Spring Harb Symp Quant Biol. 2003; 68:69-78.
• [36]Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A et al.. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet. 2007; 39:1083-1091.
• [37]Kreft KL, Verbraak E, Wierenga-Wolf AF, van Meurs M, Oostra BA, Laman JD et al.. Decreased systemic IL-7 and soluble IL-7Ralpha in multiple sclerosis patients. Genes Immun. 2012; 13:587-592.
• [38]Crawley AM, Faucher S, Angel JB. Soluble IL-7R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection. J Immunol. 2010; 184:4679-4687.
• [39]Hartling HJ, Thorner LW, Erikstrup C, Harritshoj LH, Kronborg G, Pedersen C et al.. Polymorphism in interleukin-7 receptor alpha gene is associated with faster CD4(+) T-cell recovery after initiation of combination antiretroviral therapy. AIDS. 2014; 28:1739-1748.
• [40]Santiago JL, Alizadeh BZ, Martinez A, Espino L, de la Calle H, Fernandez-Arquero M et al.. Study of the association between the CAPSL-IL7R locus and type 1 diabetes. Diabetologia. 2008; 51:1653-1658.
• [41]Guo L, Du Y, Chang S, Zhang K, Wang J. rSNPBase: a database for curated regulatory SNPs. Nucleic Acids Res. 2014; 42:D1033-D1039.
• [42]Broux B, Hellings N, Venken K, Rummens JL, Hensen K, Van Wijmeersch B et al.. Haplotype 4 of the multiple sclerosis-associated interleukin-7 receptor alpha gene influences the frequency of recent thymic emigrants. Genes Immun. 2010; 11:326-333.
• [43]Page EE, Nelson M, Kelleher P. HIV and hepatitis C coinfection: pathogenesis and microbial translocation. Curr Opin HIV AIDS. 2011; 6:472-477.
• [44]Jager J, Schulze C, Rosner S, Martin R. IL7RA haplotype-associated alterations in cellular immune function and gene expression patterns in multiple sclerosis. Genes Immun. 2013; 14:453-461.
• [45]Garcia-Samaniego J, Rodriguez M, Berenguer J, Rodriguez-Rosado R, Carbo J, Asensi V et al.. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol. 2001; 96:179-183.
• [46]Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B et al.. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS. 2008; 22:2135-2141.
• [47]Ciuffreda D, Kim AY. Update on hepatitis C virus-specific immunity. Curr Opin HIV AIDS. 2011; 6:559-565.
• [48]Perneger TV. What’s wrong with Bonferroni adjustments. BMJ. 1998; 316:1236-1238.
• [49]Sterne JA, Davey Smith G. Sifting the evidence-what’s wrong with significance tests? BMJ. 2001; 322:226-231.
• [50]Burton PR, Tobin MD, Hopper JL. Key concepts in genetic epidemiology. Lancet. 2005; 366:941-951.